NewAmsterdam Pharma Co

NewAmsterdam Pharma Co

NAMS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +36.5% in FY2025

Michael Davidson is the CEO of NewAmsterdam Pharma Co and was paid $13.6M in FY2025 (Dec), up 111%.

Pay$100 in the stock at the end of FY23 → $314
CEO pay is from each NewAmsterdam Pharma Co proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Michael DavidsonFY2025
  2. 2Douglas KlingFY2025
  3. 3John Kastelein, M.D., Ph.D. FESCFY2025
  4. 4Ian SomaiyaFY2025
  5. 5Louise KooijFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

NewAmsterdam Pharma Co paid its 5 named executives $30.8M in total in FY2025 (Dec). CEO Michael Davidson was paid $13.6M of that.

Name
Michael DavidsonChief Executive OfficerNot disclosed
Douglas KlingChief Operating OfficerNot disclosed
John Kastelein, M.D., Ph.D. FESCChief Scientific Officer
Ian SomaiyaChief Financial OfficerNot disclosed
Louise KooijChief Accounting OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers24

See all

The FY2025 (Dec) proxy of NewAmsterdam Pharma Co names 24 peer companies for pay. Among NewAmsterdam Pharma Co and these peers, CEO pay was 5th highest of 11 and total shareholder return was 7th highest of 11.

5th highest of 11in NewAmsterdam Pharma Co and its pay peers, FY2025 (Dec) by CEO pay:

$6.6M$33.3M

7th highest of 11in NewAmsterdam Pharma Co and its pay peers, FY2025 (Dec) by total shareholder return:

$107$625

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Nicholas Downing, M.D.Director · 1 yr on the boardIndependentNomination and Corporate Governance—Paid as an executive
  • Janneke van der KampDirector · 0 yr on the boardIndependentCompensation—Paid as an executive
  • John W. SmitherDirector · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    NewAmsterdam Pharma Co CEO pay rose 111% to $13.6M. The stock rose 36% in FY2025 (Dec).
    DEF 14A
  2. Pay
    NewAmsterdam Pharma Co CFO pay rose 275% to $4.7M. The stock rose 36% in FY2025 (Dec).
    DEF 14A
  3. Pay
    NewAmsterdam Pharma Co Chief Scientific Officer pay rose 42% to $4.8M. The stock rose 36% in FY2025 (Dec).
    DEF 14A
  4. Pay
    NewAmsterdam Pharma Co Chief Scientific Officer pay rose 14% to $3.4M. The stock rose 130% in FY2024 (Dec).
    DEF 14A
  5. Pay
    NewAmsterdam Pharma Co COO pay rose 111% to $5.4M. The stock rose 36% in FY2025 (Dec).
    DEF 14A
  6. Board
    John W. Smither joined the board of NewAmsterdam Pharma Co. John W. Smither sits on no other public board.
    3
  7. Board
    Janneke van der Kamp joined the board of NewAmsterdam Pharma Co. Janneke van der Kamp sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AMay 6, 2026FY2025
Annual report10-KFeb 18, 2026FY2025
Proxy statementDEF 14AMay 8, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AMay 9, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data